Related Experiment Video
Updated: Apr 1, 2026
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Attention and Executive Functions Are the Most Vulnerable Cognitive Domains in Patients With Drug-Resistant Epilepsy
Niina Lähde1,2, Pabitra Basnyat1,2, Hanna Lehtinen1
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Background:
Cognitive impairments are prevalent among patients with drug-resistant epilepsy (DRE) referred for neurostimulation therapies. However, the performance characteristics across various cognitive domains in this patient group are not well established.
Objective:
To analyze the characteristics and severity of cognitive impairment in patients with DRE referred for neurostimulation therapy, specifically vagus nerve stimulation (VNS) or deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS).
Methods:
The study included 53 consecutive patients with DRE who were considered for either VNS or ANT-DBS therapy. As part of the preimplantation clinical protocol, all patients underwent neuropsychological evaluation. Cognitive tests were categorized into four domains: (1) attention and executive functions (AEFs), (2) memory and learning, (3) language functions, and (4) visual functions. Test performance was compared against established normative data.
Results:
More than one-third of the patients exhibited cognitive impairment across all four assessed domains. Deficits in AEFs were the most prevalent and severe, affecting 66% of the cohort. These impairments were especially pronounced in patients treated with topiramate or zonisamide, as well as in those referred for ANT-DBS.
Conclusions:
The presurgical neuropsychological evaluation of patients with DRE considered for neurostimulation therapy should place particular emphasis on AEFs. This focus provides a critical baseline for follow-up and enables targeted monitoring of cognitive outcomes during neurostimulation treatment.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
09:00Investigating the Function of Deep Cortical and Subcortical Structures Using Stereotactic Electroencephalography: Lessons from the Anterior Cingulate Cortex
Published on: April 15, 2015
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...